AKEBIA THERAPEUTICS INC (AKBA)
Health Care · Biopharmaceuticals · NASDAQ
A biopharmaceutical company specializing in commercializing treatments for kidney disease complications and developing a pipeline of novel therapies for rare renal disorders.
What AKEBIA THERAPEUTICS INC does
Akebia Therapeutics is a biopharmaceutical company focused on the development and commercialization of therapeutics for kidney disease. Its commercial portfolio includes Vafseo for anemia due to chronic kidney disease in dialysis patients and Auryxia for the control of serum phosphorus levels and treatment of iron deficiency anemia in chronic kidney disease patients. The company is also advancing a pipeline of mid-stage and early-stage candidates targeting rare kidney diseases and other related indications.
Recent developments
In Q2 2026, Vafseo net revenue grew 34% sequentially to $21.3 million with over 10,500 active patients. The company initiated a Phase 2 basket trial for its complement inhibitor candidate ebribafusp, with initial data expected in 2027. Additionally, an interim analysis of the VOICE trial demonstrated significant improvement in safety outcomes for Vafseo compared to existing standard-of-care treatments.
From AKEBIA THERAPEUTICS INC's filing of 2026-08-05.
Themes: kidney disease, anemia treatment, rare kidney disease, complement-mediated disease, HIF-based therapies
Fundamentals
- Price$0.8148 as of 2026-10-08 close
- Market cap$226M as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return-71.4% 2025-10-08 close $2.85 → 2026-10-08 close $0.8148
- P/En/a negative earnings
- Net margin-2.3% FY2025, SEC XBRL
- ROE-16.4% FY2025, SEC XBRL
- Debt / equity7.69 as of 2026-09-03
- Revenue growth (YoY)+7.5% as of 2026-09-03
- Revenue CAGR (3y)-6.9% SEC XBRL
- Beta1.13 as of 2026-09-03
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How AKBA compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How AKEBIA THERAPEUTICS INC looks technically
AKEBIA THERAPEUTICS INC (AKBA) is trading 33.4% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 227 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 10, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 37, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It just made a new 20-day low, breaking below its recent trading range. It is trading right at its lowest price of the past year (its 52-week low).
Trend
8
| Distance from the 200-day | it is trading 33.4% below its 200-day average, the long-term trend line — a long-term downtrend | -33.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $0.9534 | $0.9534 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.22 | $1.22 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 1. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 227 trading days ago — a "death cross", a bearish long-term signal | 227 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 10, below the 25 that marks a real trend) | 10.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 37, neither overbought (above 70) nor oversold (below 30) | 36.8 |
|---|---|---|
| Position in its 14-day range | it is trading right at the bottom of its 14-day range ($0.8148 to $1.00) — its "stochastic" reading is 0 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 0.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $3.20 | $3.20 |
|---|---|---|
| From the 52-week high | it is 74.5% below its 52-week high (its highest price of the past year) | -74.5% |
| Above the 52-week low | it is trading right at its lowest price of the past year (its 52-week low) | +0.0% |
| Below the 52-week high | it is 74.5% below its highest point of the past year | 74.5% |
| Since a 20-day breakout | it just made a new 20-day low, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $31.00 (set on 2014-06-20) | $31.00 |
| Given back of the 52-week move | over the past year its closes ranged ($0.8148 to $3.17), and it has recovered essentially none of its fall from last year’s high — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.27 to $2.35. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 97.4% below its all-time high | -97.4% |
| Nearest price level | it is trading 7.1% below a resistance level at $0.8725 — a price it turned at twice since 2026-05-19, most recently on 2026-09-17. Since 2024-10-08 it has 0 such levels below the current price and 13 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +7.1% |
| All-time low | its lowest closing price on record is $0.241 (set on 2022-10-24) | $0.241 |
| Above the all-time low | it is 238.1% above its all-time low | +238.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 80% of it) | 20th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.0525 between its high and its low — about 6.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.0525 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $0.83 and $0.98 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $0.83 – $0.91 – $0.98 |
| Typical daily range (% of price) | its price moves about 6.4% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.4% |
| Stretch from the 200-day average | it is trading 7.8 daily ranges below its 200-day average price (33.4% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.96× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bearish engulfing | 7 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 7 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 2.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -2.4% |
|---|---|---|
| Open gap | it gapped 2.4% below the previous close today and has not traded back through the level it left behind at 0.87 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.4% |
| Gap filled | a 2.4% gap up opened on 2026-09-11 has been "filled" 18 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 18 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -10.56% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 21.9 percentage points (the stock lost 20.9% while the market gained 1.0%) | -21.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 46.4 percentage points (the stock lost 42.6% while the market gained 3.8%) | -46.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 55.7 percentage points (the stock lost 38.3% while the market gained 17.5%) | -55.7% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 86.4 percentage points (the stock lost 71.4% while the market gained 15.0%) | -86.4% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 18% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 17.1% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -18.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 27% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $1.11 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | -26.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 12% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $0.9228 — a volume-weighted average of daily closes over 46 sessions, not a true tick-by-tick VWAP. | -11.7% |
Head and shoulders, bearish — forming · entry $0.7862 · 90 sessions in
Inverse head and shoulders, bullish — broke out · entry $0.9348 · 82 sessions in
Price levels it has turned at before
AKBA last closed at $0.8148 on 2026-10-08. Since 2024-10-08 it has turned at 0 prices below its last close and 13 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $0.8725 | Resistance | 7.1% above the last close | turned there twice · 2026-05-19 to 2026-09-17 |
| $1.19 | Resistance | 45.4% above the last close | turned there twice · 2026-03-05 to 2026-07-23 |
| $1.35 | Resistance | 66.3% above the last close | turned there twice · 2026-04-29 to 2026-07-30 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $1.00.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 8 trading days, since 2026-09-29.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Near the 52-week low · Pulled back from the 12-month high · Broke down to a new 20-day low · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$3.92 range $1.00 – $6.00; median $4.00
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AKBA
- Consensus EPS estimate-$0.03 next reporting period, as of 2026-10-08
- Estimate change, 30 days+$0.01 from -$0.04, on 2026-09-07, 31-day window
- Readings revised upward17% of 6 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High reliance on the successful commercial adoption of Vafseo and the impact of generic competition on Auryxia revenue.","Unprofitability and the requirement for continued capital, including the necessity to refinance debt obligations.","Significant regulatory and development risks inherent in clinical-stage pharmaceutical pipeline assets."]
What changed in the latest 10-Q
AI-assisted comparison of AKBA's 10-Q filed 2026-08-05 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-05) identifies the mid-stage pipeline asset as 'ebribafusp' alongside praliciguat.
- Newer filing (2026-08-05) states that in August 2026, the company announced the initiation of a Phase 2 basket study to evaluate ebribafusp in IgA Nephropathy, C3 Glomerulopathy, and Lupus Nephritis.
- Newer filing (2026-08-05) includes 'Mylan Therapeutics, Inc., or AG Distributor' as a customer for Auryxia.
- Removed:
- Older filing (2026-05-07) includes statistics on CKD impact: approximately 35.5 million patients affected in the U.S., and 2022 estimated costs of $95.7 billion for treating Medicare beneficiaries with CKD and $45.3 billion for treating people on dialysis.
- Older filing (2026-05-07) states the current U.S. market opportunity for anemia due to CKD in dialysis patients is approximately $1 billion based on ESA pricing.
- Older filing (2026-05-07) states Vafseo commercial supply agreements at market entry covered dialysis organizations caring for nearly 100% of U.S. dialysis patients.
- Older filing (2026-05-07) states approximately 290,000 dialysis patients in the U.S. currently have prescribing access to Vafseo.
- Older filing (2026-05-07) includes a section describing exclusive rights under patents for Auryxia that protected against generic competition until March 20, 2025 (the older text appears truncated at this point).
- Reworded:
- The asset previously referred to as 'AKB-097' in the older filing (2026-05-07) is referred to as 'ebribafusp (AKB-097)' in the newer filing (2026-08-05).
- Older filing (2026-05-07) stated the company expected to initiate a Phase 2 basket study in the second half of 2026; newer filing (2026-08-05) states the initiation was announced in August 2026.
- Notes:
- The older filing text is truncated at 'since Marc', so changes beyond that point cannot be assessed.
- The newer filing text is truncated at 'changes in a firm purchase commitment liabil', so changes beyond that point cannot be assessed.
Risk Factors
- Added:
- Newer filing (2026-08-05) adds a paragraph stating that in March 2026, Teva Pharmaceuticals Ltd. received approval for an Abbreviated New Drug Application (ANDA) for a generic version of Auryxia, and that the company has experienced and expects to continue to experience a significant reduction in Auryxia sales volume as a result.
- Newer filing (2026-08-05) adds a statement that the estimated sufficiency of cash resources for at least two years is contingent upon refinancing the outstanding debt under the senior secured term loan facility to defer principal payments that would otherwise commence on January 1, 2027.
- Newer filing (2026-08-05) adds a statement that if refinancing of the senior secured term loan facility cannot be executed on favorable terms or at all, existing cash resources and expected revenues are believed sufficient to fund the current operating plan for at least 12 months from the filing of the Form 10-Q.
- Newer filing (2026-08-05) adds a reference to Note 7, Indebtedness, in the unaudited condensed consolidated financial statements for additional information regarding obligations under the senior secured term loan facility.
- Newer filing (2026-08-05) adds net loss figures for the three and six months ended June 30, 2026 ($8.9 million and $18.0 million, respectively).
- Newer filing (2026-08-05) adds references to the authorized generic version of Auryxia and the authorized generic distribution partner, Mylan Therapeutics, Inc. (AG Distributor), in the discussion of Auryxia revenue.
- Newer filing (2026-08-05) adds a reference to 'the extent that we, or our collaboration partners,' in the bullet point regarding obtaining and maintaining market acceptance.
- Newer filing (2026-08-05) adds a reference to 'the extent to which we or our collaboration partners are able to obtain and maintain adequate market share' in the bullet point regarding market size.
- Removed:
- Older filing (2026-05-07) includes the phrase 'including to commercialize Vafseo and Auryxia and advance our existing programs' in the statement about the sufficiency of existing cash resources for at least two years, which is removed in the newer filing.
- Older filing (2026-05-07) includes a net loss figure of $9.1 million for the three months ended March 31, 2026, which is removed in the newer filing.
- Older filing (2026-05-07) includes the phrase 'which depends on several factors' in the sentence introducing the bulleted factors for generating product revenue, which is removed in the newer filing.
- Reworded:
- Newer filing changes 'commercializing Auryxia and Vafseo' to 'commercializing our two approved products, Auryxia and Vafseo'.
- Newer filing changes 'Prior to our 2018 merger, or the Merger, with Keryx Biopharmaceuticals' to 'Prior to our 2018 merger, or the Keryx Merger, with Keryx Biopharmaceuticals'.
- Newer filing changes 'United States, or U.S., Food and Drug Administration' to 'U.S. Food and Drug Administration'.
- Newer filing changes 'we have incurred net losses each year since our inception, including a net loss of $9.1 million for the three months ended March 31, 2026' to 'Since inception, we have incurred net losses each year, including a net loss of $8.9 million and $18.0 million for the three and six months ended June 30, 2026, respectively'.
- Newer filing changes the accumulated deficit date from 'As of March 31, 2026' to 'As of June 30, 2026'.
- Newer filing changes 'obtaining and maintaining market acceptance of Auryxia, Vafseo and any other product candidate' to 'the extent that we, or our collaboration partners, are able to obtain and maintain market acceptance of Auryxia, the authorized generic version of Auryxia, Vafseo and any of our other product candidate'.
- Newer filing changes 'the size of any market in which Auryxia, Vafseo and any other product or product candidate... receives approval and obtaining adequate market share' to 'the size of any market for our approved products or any product candidates that may be approved, and the extent to which we or our collaboration partners are able to obtain and maintain adequate market share'.
- Newer filing changes 'maintaining marketing approvals for Auryxia, Vafseo and any other product' to 'maintaining marketing approvals for Auryxia, Vafseo and any other product candidate that may be approved'.
- Newer filing changes 'our ability to maintain contracts with dialysis organizations for the sale of Auryxia and Vafseo in the U.S.' to 'our ability to maintain contracts with dialysis organizations for the sale of Auryxia and Vafseo in the U.S. on favorable terms, or at all'.
- Newer filing changes 'the timing and number of additional generic versions of Auryxia that enter the market following loss of exclusivity, or LoE, for Auryxia which occurred in March 2025' to 'the timing and number of additional generic versions of Auryxia that enter the market following loss of exclusivity, or LoE, for Auryxia that occurred in March 2025'.
- Notes:
- The newer filing text appears to be truncated at 'establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate supplies of pr' and the older filing text appears to be truncated at 'If Medice's launch', so changes after these points in the Risk Factors section could not be compared.
- Only the text provided in the prompt was compared; no other sections of either filing were reviewed.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 180 days · read to 2026-10-040 buys · 1 sell ($62181) — 1 selling insider
Most recent open-market transaction: 2026-06-29. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AKBA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding AKBA as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 32,435,967
- Reported value $36,977,002
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about AKBA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
AKBA had 20,504,915 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
AKBA had 7.40% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.76 days to cover at the same settlement.
- Reported short interest (shares) 20,504,915
- Short interest (% of shares outstanding) 7.40%
- Prior settlement (shares) 23,002,561
- Reported change -10.86%
- Days to cover (reported) 2.76
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amgen (AMGN)
- FibroGen (FGEN)
- GlaxoSmithKline (GSK)
- Johnson & Johnson (JNJ)
- Teva Pharmaceutical Industries (TEVA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AKBA vs…
Frequently asked questions
What does AKEBIA THERAPEUTICS INC (AKBA) do?
Akebia Therapeutics is a biopharmaceutical company focused on the development and commercialization of therapeutics for kidney disease. Its commercial portfolio includes Vafseo for anemia due to chronic kidney disease in dialysis patients and Auryxia for the control of serum phosphorus levels and treatment of iron deficiency anemia in chronic kidney disease patients.
What sector is AKEBIA THERAPEUTICS INC (AKBA) in?
AKEBIA THERAPEUTICS INC (AKBA) is classified in the Health Care sector. Its industry is Biopharmaceuticals. It trades on NASDAQ.
Who are AKEBIA THERAPEUTICS INC's (AKBA) competitors?
Notable peers of AKEBIA THERAPEUTICS INC (AKBA) include Amgen, FibroGen, GlaxoSmithKline, Johnson & Johnson and Teva Pharmaceutical Industries. This peer set is informational only — not financial advice.
Is AKEBIA THERAPEUTICS INC (AKBA) overbought or oversold right now?
AKEBIA THERAPEUTICS INC (AKBA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 37, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AKBA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.